Target intelligence / Profile preview

Lactococcus lactis W58 (L. lactis W58)

Target
L. lactis W58
Molecular classification
Probiotic, Gram-positive bacteria, Lactic acid bacteria
01

Overview

Lactococcus lactis W58 is a specific probiotic strain of the Gram-positive, non-pathogenic bacterium Lactococcus lactis, which is widely utilized in both the food industry and as a live biotherapeutic agent. It is a key component of specialized multi-strain probiotic formulations, such as Ecologic Barrier and OMNi-BiOTiC PANDA, selected for its documented ability to strengthen the intestinal epithelial barrier. The strain functions by enhancing the expression and assembly of tight junction proteins, thereby reducing intestinal permeability (often referred to as "leaky gut") and preventing the systemic translocation of pro-inflammatory bacterial components like lipopolysaccharides (LPS). Clinical research has investigated L. lactis W58 for its potential to manage conditions linked to gut-derived inflammation, including migraine, depression, and metabolic disorders, by modulating the host's immune response and microbiome composition. While generally recognized as safe (GRAS), it represents a live microbial intervention rather than a traditional molecular drug target like a receptor or enzyme.

Other names
Lactococcus lactis subsp. lactis W58Streptococcus lactis W58
02

Mechanism of action

Enhancement of tight junction protein expression, competitive exclusion of pathogenic bacteria, and reduction of pro-inflammatory cytokine production (e.g., IL-6, TNF-alpha).

03

Biological functions

Gut barrier reinforcementImmune modulationPathogen inhibitionLactic acid productionShort-chain fatty acid (SCFA) production
04

Disease associations

Intestinal hyperpermeabilityInflammatory bowel diseaseDepressionMigraineMetabolic syndromeAtopic dermatitis
05

Safety considerations

Risk of opportunistic infection in immunocompromised individualsPotential for antibiotic resistance gene transferSafety in neonates with immature gastrointestinal tracts
06

Interacting drugs

Antibiotics
07

Biomarkers

ZonulinLipopolysaccharide (LPS)Fecal calprotectinC-reactive protein (CRP)

Beyond the preview

Go deeper on Lactococcus lactis W58 (L. lactis W58).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lactococcus lactis W58 (L. lactis W58).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call